Article
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Blood - 9 Feb 2023
Moujalled Donia M, Brown Fiona C, Chua Chong Chyn, Dengler Michael A, Pomilio Giovanna, Anstee Natasha S, Litalien Veronique, Thompson Ella, Morley Thomas, MacRaild Sarah, Tiong Ing S, Morris Rhiannon, Dun Karen, Zordan Adrian, Shah Jaynish, Banquet Sebastien, Halilovic Ensar, Morris Erick, Herold Marco J, Lessene Guillaume, Adams Jerry M, Huang David C S, Roberts Andrew W, Blombery Piers, Wei Andrew H
Abstract excerpt
Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical trials are actively exploring the role of venetoclax in combination with intensive chemotherapy in fitter patients with AML. As most patients still develop recurrent disease, improved understanding of relapse mechanisms is needed. We find...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.